Insiders Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq Other stock markets 21:00:00 07/05/2024 BST			5-day change	1st Jan Change
0.92 ^USD	-4.17%		-14.02%	-12.38%

04-01	Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-26	Transcript : Quince Therapeutics, Inc. - Special Call

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quince Therapeutics, Inc. Launches Scientific Advisory Board	02-22	CI
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	02-15	CI
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	26/10/23	CI
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23/10/23	CI
Quince Therapeutics Appoints Charles S. Ryan as President	06/09/23	CI
Insider Buy: Quince Therapeutics	11/08/23	MT
Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023	10/08/23	CI
Quince Therapeutics, Inc. Announces Board and Executive Changes	24/07/23	CI
Philip Low Resigns as Member of the Board of Directors of Quince Therapeutics, Inc	28/03/23	CI
Quince Therapeutics, Inc. Announces Executive Changes	03/03/23	CI
Quince Therapeutics, Inc. Announces Resignation of Marwan Sabbagh Member of the Board of Directors	30/09/22	CI
Cortexyme, Inc. will Change its Name to Quince Therapeutics	01/08/22	CI
Cortexyme, Inc. Announces Resignation of Leslie Holsinger as Executive Vice President of Research and Development, Effective July 31, 2022	22/07/22	CI
Cortexyme, Inc. Appoints June Bray to its Board of Directors	13/06/22	CI
Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer	10/06/22	CI
Cortexyme, Inc. Announces Executive Changes	10/06/22	CI
Cortexyme, Inc. Announces Departure of Caryn McDowell as Chief Legal and Administrative Officer and Corporate Secretary, Effective as of July 8, 2022	20/05/22	CI
Cortexyme Appoints Dr. Philip Low to Its Board of Directors	20/05/22	CI
Cortexyme to Buy Novosteo	10/05/22	MT
Dr. Dirk Thye and Philip Low to Join Cortexyme Board	10/05/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Insiders

Filters